145 Investor presentation First nine months of 2022 Net profit has been converted to shareholders DKK billion 50 40 Cash conversion and allocation (2021) 48 (100%) 48 (100%) 41 (86%) 30 19 20 29 10 22 0 Net profit Free cash flow Cash return Share buyback Dividends Note: Cash used for the acquisition of Dicerna Pharmaceuticals was 18,282 million DKK per note 5.3 of the 2021 Novo Nordisk Annu R&D: Research and Develoment; CAPEX: Capital expenditure; EBITDA: Earnings before interest, taxes, depreciation and amortisatio
Download PDF file